

CURRICULUM VITAE:
Prof.ssa PAOLA FADDA

-Dicembre 2017 ad oggi

Professore Ordinario di Farmacologia (Settore Scientifico –disciplinare BIO/14) Università di Cagliari, Dipartimento di Scienze Biomediche, Sezione di Neuroscienze e Farmacologia Clinica, Facoltà di Medicina e Chirurgia.

- Maggio 2006 a Dicembre 2017

Professore Associato di Farmacologia (Settore Scientifico –disciplinare BIO/14) Università di Cagliari, Dipartimento di Scienze Biomediche, Sezione di Neuroscienze e Farmacologia Clinica, Facoltà di Medicina e Chirurgia.

- Gennaio-2004 al Dicembre 2006

Research Assistant (presso School of Medical Science (Biomedical Sciences) University of Aberdeen (Scotland UK)

-Maggio-Dicembre- 2003

Visiting Research presso i laboratori del Prof. RG. Pertwee e del Dr. G.Riedel Department Biomedical Sciences University of Aberdeen (Scotland UK)

- 1997-2006

Ricercatore Universitario Facoltà di Medicina e Chirurgia, Settore Scientifico–disciplinare BIO/14- Farmacologia Dipartimento di Neuroscienze dell'Università di Cagliari (confermato da 24 Novembre 2000)

- 1989- 1997

Ricercatore presso il Centro per la Neurofarmacologia, Consiglio Nazionale delle Ricerche (CNR), Cagliari.

- 1988-1989

Laureato Interno con attività di ricerca presso Dipartimento di Neuroscienze "B.B.Brodie" dell'Università di Cagliari.

- 1988-1989

Borsa di Studio della "FIDIA Research Laboratories" di AbanoTerme(Padova).

INCARICHI ACCADEMICI

- dal Novembre 2012 a 30 Giugno 2018 **Presidente Classe delle Professioni Infermieristiche** (Corso di Laurea in Infermieristica; Corso di Laurea Scienze Infermieristiche ed Ostetriche Università degli Studi di Cagliari
- dal 2018 al 2020 **Commissario Commissione scatti stipendiali** Università degli Studi di Cagliari
- dal Settembre 2015 ad oggi **Componente del Consiglio Comitato Unico di Garanzia (CUG)** Università degli Studi di Cagliari

- dal 2017 ad oggi **Componente Consiglio di Facoltà Medicina e Chirurgia** Università degli Studi di Cagliari
- dal 2017 ad oggi **Componente Commissione Paritetica** - Facoltà di Medicina e Chirurgia Università degli Studi di Cagliari
- dal 2018 ad oggi **Componente Team Progetto di Ateneo (SUPERA- Supporting the Promotion of Equality in Research and Academia)** sulle questioni di genere finanziato nell'ambito del programma **European Union's Horizon 2020 Research and Innovation Programme** Università degli Studi di Cagliari
- dal Settembre 2018 al 13 Ottobre 2020 **Coordinatore Commissione Mobilità Internazionale** Facoltà di Medicina e Chirurgia- Università degli Studi di Cagliari
- Ottobre 2019 ad oggi **Coordinatore Dottorato Internazionale in Neuroscienze** Università degli Studi di Cagliari
- 17 Settembre 2020 Sorteggiata **Componente del GEV Disciplinare per l'Area 5 - Scienze biologiche per la Valutazione della Qualità della Ricerca 2015-19-** AGENZIA NAZIONALE DI VALUTAZIONE DEL SISTEMA UNIVERSITARIO E DELLA RICERCA – ANVUR

INCARICHI in Società Scientifiche

- Dal 1 gennaio 2018 ad oggi **Consigliere Società Italiana di Neuroscienze (SINS)**

-

AFFILIAZIONI ATTUALI:

- Dipartimento di Scienze Biomediche, Università di Cagliari.
- Centro di Eccellenza “Neurobiologia delle Dipendenze”, Università di Cagliari
- Istituto Nazionale di Neuroscienze
- Consiglio Nazionale di Neuroscienze, ISTITUTO DI NEUROSCIENZE del CNR, Sezione di Cagliari.

PARTECIPAZIONE AL COLLEGIO DEI DOCENTI OVVERO ATTRIBUZIONE DI INCARICHI DI INSEGNAMENTO, NELL'AMBITO DI DOTTORATI DI RICERCA ACCREDITATI DAL MINISTERO

Partecipazione al collegio dei docenti del dottorato in neuroscienze Università di Cagliari come rilevabile dal sito CINECA dal 05-01-2007 a oggi

AFFILIAZIONI PRINCIPALI SOCIETA' SCIENTIFICHE:

- * Società Italiana di Farmacologia SIF (socio)
- * Società Italiana di Neuroscienze SINS (Componente del Consiglio)
- * Società Italiana di Neuropsicofarmacologia SINPF (socio)
- * Mediterranean Neuroscience Society MNS (socio)
- * Society for Neuroscience SFN, USA (member)
- * International Cannabinoid Research Society ICRS, USA (member)

Lista delle pubblicazioni:

1. Pintori, N, Miliano C, Castelli MP, Simola N, **Fadda P**, Fattore L, Scherma M, Ennas MG, Flore G, De Felice M, Sagheddu C, Pistis M, Di Chiara G, De Luca MA. [Repeated exposure to jwh-018 induces adaptive changes in the mesocorticolimbic dopamine pathways, glial cells alteration and behavioural correlates](#) *Br. J Pharmacol* (submitted)
2. Boi L, Pisanu A, Fusco G, Carboni E, Casu MA, Satta V, Scherma M, Janda E, Palmas MF, Mocchi I, Ena A, Mulas G, Spiga S, **Fadda P**, De Simone A, Carta AR. [Modeling Parkinson's disease neuropathology and symptoms by intranigral inoculation of preformed human \$\alpha\$ -synuclein oligomers.](#) *International Journal of Molecular Sciences* (submitted)
3. Fattore L, **Fadda P**, Zanda MT, Fratta W. [Analysis of Opioid-Seeking Behavior Through the Intravenous Self-Administration Reinstatement Model in Rats.](#) *Methods Mol Biol.* 2021;2201:231-245. doi: 10.1007/978-1-0716-0884-5_21.PMID: 32975804
4. Scherma M, Fattore L, Fratta W, **Fadda P**. [Conditioned Place Preference \(CPP\) in Rats: From Conditioning to Reinstatement Test.](#) *Methods Mol Biol.* 2021;2201:221-229. doi: 10.1007/978-1-0716-0884-5_20.PMID: 32975803
5. Scherma M, Muntoni AL, Riedel G, Fratta W, **Fadda P**. [Cannabinoids and their therapeutic applications in mental disorders.](#) *Dialogues . Clinical Neuroscience*, 2020 Vol 22, No 3
6. Scherma M, Qvist JS, Asok A, Huang SC, Masia P, Deidda M, Wei YB, Soni RK, Fratta W, **Fadda P**, Kandel ER, Kandel DB, Melas PA. [Cannabinoid exposure in rat adolescence reprograms the initial behavioral, molecular, and epigenetic response to cocaine.](#) *Proc Natl Acad Sci U S A.* 2020 May 5;117(18):9991-10002. doi: 10.1073/pnas.1920866117. Epub 2020 Apr 20.
7. D'Addario C, Zaplatic E, Giunti E, Pucci M, Micioni Di Bonaventura MV, Scherma M, Dainese E, Maccarrone M, Nilsson IA, Cifani C, **Fadda P**. [Cannabinoid exposure in rat adolescence reprograms the initial behavioral, molecular, and epigenetic response to cocaine.](#) *Int J Eat Disord.* 2020 May;53(5):432-446. doi: 10.1002/eat.23271. Epub 2020 Apr 10.PMID: 32275093
8. Collu R, Post JM, Scherma M, Giunti E, Fratta W, Lutz B, **Fadda P**, Bindila L. [Epigenetic regulation of the cannabinoid receptor CB1 in an activity-based rat model of anorexia nervosa.](#) *Biochim Biophys Acta Mol Cell Biol Lipids.* 2020 Apr;1865(4):158578. doi: 10.1016/j.bbalip.2019.158578. Epub 2019 Nov 26. PMID: 31778792
9. Lecca S, Luchicchi A, Scherma M, **Fadda P**, Muntoni AL, Pistis M. [\$\Delta\$ 9-Tetrahydrocannabinol During Adolescence Attenuates Disruption of Dopamine Function Induced in Rats by Maternal Immune Activation.](#) *Front Behav Neurosci* 2019 Sep 6;13:202. doi: 10.3389/fnbeh.2019.00202. eCollection 2019.
10. Scherma M, Giunti E, Fratta W, **Fadda P**. [Gene knockout animal models of depression, anxiety and obsessive compulsive disorders.](#) *Psychiat Genet* 2019 Oct;29(5):191-199. doi: 10.1097/YPG.0000000000000238

11. Collu R, Scherma M, Piscitelli F, Giunti E, Satta V, Castelli MP, Verde R, Fratta W, Bisogno T, **Fadda P**. [Impaired brain endocannabinoid tone in the activity-based model of anorexia nervosa](#). *Int J Eat Disord* 2019 Nov; 52 1(1): 1251-1962doi: 10.1002/eat.23157.Epub 2019 Aug 27.
12. Scherma M, Collu R, Satta V, Giunti E, **Fadda P**. [Animal Models of Eating Disorders](#). *Methods Mol Biol*. 2019; 2011:297-314. doi: 10.1007/978-1-4939-9554-7_17.
13. Sagheddu C, Scherma M, Congiu M, **Fadda P**, Carta G, Banni S, Wood JT, Makriyannis A, Malamas MS, Pistis M. [Inhibition of N-acyl ethanolamine acid amidase reduces nicotine-induced dopamine activation and reward](#). *Neuropharmacology*. 2019 Jan;144:327-336. doi: 10.1016/j.neuropharm.2018.11.013. Epub 2018 Nov 12.
14. Scherma M, Masia P, Satta V, Fratta W, **Fadda P**, Tanda G. [Brain activity of anandamide: a rewarding bliss?](#) *Acta Pharmacol Sin*. 2019 Mar;40(3):309-323. doi: 10.1038/s41401-018-0075-x. Epub 2018 Jul 26. Review.
15. Scherma M, Masia P, Deidda M, Fratta W, Tanda G, **Fadda P**. [New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders](#). *Medicines (Basel)*. 2018 Oct 2;5(4). pii: E107. doi: 10.3390/medicines5040107. Review.
16. Kononoff J, Melas PA, Kallupi M, de Guglielmo G, Kimbrough A, Scherma M, **Fadda P**, Kandel DB, Kandel ER, George O. [Adolescent cannabinoid exposure induces irritability-like behavior and cocaine cross-sensitization without affecting the escalation of cocaine self-administration in adulthood](#). *Sci Rep*. 2018 Sep 17;8(1):13893. doi: 10.1038/s41598-018-31921-5.
17. Rosas M, Porru S, Giugliano V, Antinori S, Scheggi S, **Fadda P**, Fratta W, Acquas E, Fattore L. [Sex-specific differences in cannabinoid-induced extracellular-signal-regulated kinase phosphorylation in the cingulate cortex, prefrontal cortex, and nucleus accumbens of Lister Hooded rats](#). *Behav Pharmacol*. 2018 Sep;29(6):473-481. doi: 10.1097/FBP.0000000000000395.
18. Melas PA, Qvist JS, Deidda M, Upreti C, Wei YB, Sanna F, Fratta W, Scherma M, **Fadda P**, Kandel DB, Kandel ER. [Cannabinoid Modulation of Eukaryotic Initiation Factors \(eIF2 \$\alpha\$ and eIF2B1\) and Behavioral Cross-Sensitization to Cocaine in Adolescent Rats](#). *Cell Rep*. 2018 Mar 13;22(11):2909-2923. doi: 10.1016/j.celrep.2018.02.065.
19. Frahm S, Melis V, Horsley D, Rickard JE, Riedel G, **Fadda P**, Scherma M, Harrington CR, Wischik CM, Theuring F, Schwab K. [Alpha-Synuclein transgenic mice, h- \$\alpha\$ -SynL62, display \$\alpha\$ -Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease](#). *Behav Brain Res*. 2018 Feb 26;339:153-168. doi: 10.1016/j.bbr.2017.11.025. Epub 2017 Nov 24.
20. Zanda MT, **Fadda P**, Antinori S, Di Chio M, Fratta W, Chiamulera C, Fattore L. [Methoxetamine affects brain processing involved in emotional response in rats](#). *Br J Pharmacol*. 2017 Oct;174(19):3333-3345. doi: 10.1111/bph.13952. Epub 2017 Aug 19.
21. Scherma M, Satta V, Collu R, Boi MF, Usai P, Fratta W, **Fadda P**. [Cannabinoid CB1/CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia](#). *Br J Pharmacol*. 2017 May 31. doi: 10.1111/bph.13892

22. Primavera D, Manchia M, Deriu L, Tusconi M, Collu R, Scherma M, **Fadda P**, Fratta W, Carpiniello B. [Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients \(LABSP\): a protocol for a prospective observational study](#). *BMJ Open*. 2017 May 25;7(5):e014938. doi: 10.1136/bmjopen-2016-014938
23. Struik D, **Fadda P**, Zara T, Zamberletti E, Rubino T, Parolaro D, Fratta W, Fattore L. [The anabolic steroid nandrolone alters cannabinoid self-administration and brain CB₁ receptor density and function](#). *Pharmacol Res*. 2017 Jan;115:209-217. doi:10.1016/j.phrs.2016.11.031
24. Satta V, Scherma M, Giunti E, Collu R, Fattore L, Fratta W, **Fadda P**. [Emotional profile of female rats showing binge eating behavior](#). *Physiol Behav*. 2016 Sep 1;163:136-43. doi: 10.1016/j.physbeh.2016.05.013
25. Zanda MT, **Fadda P**, Chiamulera C, Fratta W, Fattore L. [Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings](#). *Behav Pharmacol*. 2016 Sep;27(6):489-96. doi: 10.1097/FBP.0000000000000241.
26. Luchicchi A, Lecca S, Melis M, De Felice M, Cadeddu F, Frau R, Muntoni AL, **Fadda P**, Devoto P, Pistis M. [Maternal Immune Activation Disrupts Dopamine System in the Offspring](#). *Int J Neuropsychopharmacol*. 2016 Jul 5;19(7). pii: pyw007. doi: 10.1093/ijnp/pyw007.
27. Mutti A, Aroni S, **Fadda P**, Padovani L, Mancini L, Collu R, Muntoni AL, Fattore L, Chiamulera C. [The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission](#). *Psychopharmacology (Berl)*. 2016 Jun;233(12):2241-51. doi: 10.1007/s00213-016-4275-0
28. Scherma M, Muntoni AL, Melis M, Fattore L, **Fadda P**, Fratta W, Pistis M. [Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives](#). *Psychopharmacology (Berl)*. 2016 May;233(10):1765-77. doi: 10.1007/s00213-015-4196-3.
29. Scherma M, Dessì C, Muntoni AL, Lecca S, Satta V, Luchicchi A, Pistis M, Panlilio LV, Fattore L, Goldberg SR, Fratta W, **Fadda P**. [Adolescent \$\Delta\(9\)\$ -Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats](#). *Neuropsychopharmacology*. 2016 Apr;41(5):1416-26. doi: 10.1038/npp.2015.295
30. Scherma, M., Satta, V., Fratta, W., **Fadda, P.** (book chapter) [The endocannabinoid system: Anorexia nervosa and binge eating disorder](#). *Cannabinoids in Neurologic and Mental Disease* pp. 389-413 Elsevier Inc. doi: 10.1016/C2013-0-00592-0
31. Fattore L, **Fadda P**, Zanda MT, Fratta W. [Analysis of opioid-seeking reinstatement in the rat](#). *Methods Mol Biol*. 2015;1230:295-307. doi: 10.1007/978-1-4939-1708-2_25.
32. Fattore L, **Fadda P**, Antinori S, Fratta W [Role of opioid receptors in the reinstatement of opioid-seeking behavior: an overview](#). *Methods Mol Biol*. 2015;1230:281-93. doi: 10.1007/978-1-4939-1708-2_24

33. Serra V, Fattore L, Scherma M, Collu R, Spano MS, Fratta W, **Fadda P**. [Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat](#). *Psychopharmacology (Berl)*. 2015 Jan;232(1):91-100. doi: 10.1007/s00213-014-3641-z
34. Fattore L, Melis M, **Fadda P**, Fratta W. [Sex differences in addictive disorders](#). *Front Neuroendocrinol*. 2014 Aug;35(3):272-84. doi: 10.1016/j.yfrne.2014.04.
35. Amchova P, Kucerova J, Giugliano V, Babinska Z, Zanda MT, Scherma M, Dusek L, **Fadda P**, Micale V, Sulcova A, Fratta W, Fattore L. [Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms](#). *Front Neuroendocrinol*. 2014 Aug;35(3):272-84. doi: 10.1016/j.yfrne.2014.04.003
36. Castelli MP, **Fadda P**, Casu A, Spano MS, Casti A, Fratta W, Fattore L. [Male and female rats differ in brain cannabinoid CB1 receptor density and function and in behavioural traits predisposing to drug addiction: effect of ovarian hormones](#). *Curr Pharm Des*. 2014;20(13):2100-13
37. Scherma M, Fattore L, Castelli MP, Fratta W, **Fadda P**. [The role of the endocannabinoid system in eating disorders: neurochemical and behavioural preclinical evidence](#). *Curr Pharm Des*. 2014;20(13):2089-99
38. Castelli MP, Madeddu C, Casti A, Casu A, Casti P, Scherma M, Fattore L, **Fadda P**, Ennas MG. [Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity](#). *PLoS One*. 2014 May 20;9(5):e98079. doi: 10.1371/journal.pone.0098079
39. Scherma M, Fattore L, Satta V, Businco F, Pigliacampo B, Goldberg SR, Dessi C, Fratta W, **Fadda P**. [Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats](#). *Br J Pharmacol*. 2013 Jun;169(4):820-33. Doi: 10.1111/bph.12014
40. Melis M, Scheggi S, Carta G, Madeddu C, Lecca S, Luchicchi A, Cadeddu F, Frau R, Fattore L, **Fadda P**, Ennas MG, Castelli MP, Fratta W, Schilstrom B, Banni S, De Montis MG, Pistis M. [PPARα regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving α7 nicotinic acetylcholine receptors](#). *J Neurosci*. 2013 Apr 3;33(14):6203-11. doi: 10.1523/JNEUROSCI.4647-12.2013.
41. Spano MS, Fattore L, Cadeddu F, Fratta W, **Fadda P**. [Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats](#). *Psychopharmacology (Berl)*. 2013 Feb;225(3):531-42. doi: 10.1007/s00213-012-2839-1
42. Zamberletti E, Piscitelli F, Cadeddu F, Rubino T, Fratta W, **Fadda P**, Di Marzo V, Parolaro D. [Chronic blockade of CB\(1\) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation](#). *Br J Pharmacol*. 2012 Dec;167(8):1652-64. doi: 10.1111/j.1476-5381.2012.02095.x.
43. Scherma M, Justinová Z, Zanettini C, Panlilio LV, Mascia P, **Fadda P**, Fratta W, Makriyannis A, Vadivel SK, Gamaledin I, Le Foll B, Goldberg SR. [The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced](#)

- [dopamine elevations in the nucleus accumbens shell in rats](#). Br J Pharmacol. 2012 Apr;165(8):2539-48. doi: 10.1111/j.1476-5381.2011.01467.x.
44. Fattore L, Spano M, Melis V, **Fadda P**, Fratta W. [Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats](#). Br J Pharmacol. 2011 Aug;163(7):1550-62. doi: 10.1111/j.1476-5381.2011.01459.x.
45. Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, **Fadda P**, Barnes C, Redhi GH, Yasar S, Le Foll B, Tanda G, Piomelli D, Goldberg SR. [Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors](#). Biol Psychiatry. 2011 Apr 1;69(7):633-41. doi: 10.1016/j.biopsych.2010.07.009.
46. Fattore L, Melis M, **Fadda P**, Pistis M, Fratta W. [The endocannabinoid system and nondrug rewarding behaviours](#). Exp Neurol. 2010 Jul;224(1):23-36. doi: 10.1016/j.expneurol.2010.03.020.
47. Fattore L, Spano MS, Altea S, **Fadda P**, Fratta W. [Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones](#). Br J Pharmacol. 2010 Jun;160(3):724-35. doi: 10.1111/j.1476-5381.2010.00734.x.
48. Spano MS, **Fadda P**, Fratta W, Fattore L. [Cannabinoid-opioid interactions in drug discrimination and self-administration: effect of maternal, postnatal, adolescent and adult exposure to the drugs](#). Curr Drug Targets. 2010 Apr;11(4):450-61
49. Spano MS, **Fadda P**, Frau R, Fattore L, Fratta W. [Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats](#). Eur Neuropsychopharmacol. 2010 Jan;20(1):25-36. doi: 10.1016/j.euroneuro.2009.09.004.
50. Fattore L, **Fadda P**, Fratta W. [Sex differences in the self-administration of cannabinoids and other drugs of abuse](#). Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S227-36. doi: 10.1016/j.psyneuen.2009.08.008.
51. Fattore L, Spano MS, Cossu G, Scherma M, Fratta W, **Fadda P**. [Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents](#). Eur Neuropsychopharmacol. 2009 Jul;19(7):487-98. doi: 10.1016/j.euroneuro.2009.01.007.
52. Riedel G, **Fadda P**, McKillop-Smith S, Pertwee RG, Platt B, Robinson L. [Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice](#). Br J Pharmacol. 2009 Apr;156(7):1154-66.
53. Scherma M, **Fadda P**, Le Foll B, Forget B, Fratta W, Goldberg SR, Tanda G. [The endocannabinoid system: a new molecular target for the treatment of tobacco addiction](#). CNS Neurol Disord Drug Targets. 2008 Nov;7(5):468-81 NIHMSID: NIHMS524102
54. Scherma M, Panlilio LV, **Fadda P**, Fattore L, Gamaledin I, Le Foll B, Justinová Z, Mikics E, Haller J, Medalie J, Stroik J, Barnes C, Yasar S, Tanda G, Piomelli D, Fratta W, Goldberg SR. [Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester \(URB597\) reverses abuse-related behavioral and neurochemical effects](#)

- [of nicotine in rats](#). J Pharmacol Exp Ther. 2008 Nov;327(2):482-90. doi: 10.1124/jpet.108.142224
55. Fattore L, **Fadda P**, Spano MS, Pistis M, Fratta W. [Neurobiological mechanisms of cannabinoid addiction](#). Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S97-S107. doi: 10.1016/j.mce.2008.02.006
56. Braida D, Limonta V, Capurro V, **Fadda P**, Rubino T, Mascia P, Zani A, Gori E, Fratta W, Parolaro D, Sala M. [Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward](#). Biol Psychiatry. 2008 Feb 1;63(3):286-92
57. Fattore L, Spano MS, Altea S, Angius F, **Fadda P**, Fratta W. [Cannabinoid self-administration in rats: sex differences and the influence of ovarian function](#). Br J Pharmacol. 2007 Nov;152(5):795-804
58. Fattore L, **Fadda P**, Fratta W. [Endocannabinoid regulation of relapse mechanisms](#). Pharmacol Res. 2007 Nov;56(5):418-27
59. **Fadda P**, Bedogni F, Fresu A, Collu M, Racagni G, Riva MA. [Reduction of corticostriatal glutamatergic fibers in basic fibroblast growth factor deficient mice is associated with hyperactivity and enhanced dopaminergic transmission](#). Biol Psychiatry. 2007 Aug 1;62(3):235-42
60. Maj PF, Collu M, **Fadda P**, Cattaneo A, Racagni G, Riva MA. [Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist \(R\)-\(+\)-\[2,3-dihydro-5-methyl-3-\(4-morpholinyl-methyl\) pyrrolo\[1,2,3-de\]-1,4-benzoxazin-6-yl\]-1-naphthalenylmethanone](#). Eur J Neurosci. 2007 Jun;25(11):3305-11.
61. Spano MS, Fattore L, Fratta W, **Fadda P**. [The GABAB receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats](#). Neuropharmacology. 2007 Jun;52(7):1555-62.
62. Fattore L, Viganò D, **Fadda P**, Rubino T, Fratta W, Parolaro D. [Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2](#). Eur J Neurosci. 2007 Apr;25(7):2191-200.
63. Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, **Fadda P**, Fratta W. [Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats](#). Neuropharmacology. 2007 Feb;52(2):646-54
64. Fattore L, Spano MS, Deiana S, Melis V, Cossu G, **Fadda P**, Fratta W. [An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives](#). Brain Res Rev. 2007 Jan;53(1):1-16
65. **Fadda P**, Scherma M, Spano MS, Salis P, Melis V, Fattore L, Fratta W. [Cannabinoid self-administration increases dopamine release in the nucleus accumbens](#). Neuroreport. 2006 Oct 23;17(15):1629-32

66. **Fadda P**, Robinson L, Fratta W, Pertwee RG, Riedel G. [Scopolamine and MK801-induced working memory deficits in rats are not reversed by CBD-rich cannabis extracts.](#) Behav Brain Res. 2006 Apr 3;168(2):307-11
67. Fattore L, Deiana S, Spano SM, Cossu G, **Fadda P**, Scherma M, Fratta W. [Endocannabinoid system and opioid addiction: behavioural aspects.](#) Pharmacol Biochem Behav. 2005 Jun;81(2):343-59
68. Fattore L, Spano S, Cossu G, Deiana S, **Fadda P**, Fratta W. [Cannabinoid CB\(1\) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats.](#) Neuropharmacology. 2005; 48(8):1097-104.
69. **Fadda P**, Scherma M, Fresu A, Collu M, Fratta W. [Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA/2J and C57BL/6J mice.](#) Synapse. 2005 Apr;56(1):29-38.
70. **Fadda P**, Robinson L, Fratta W, Pertwee RG, Riedel G. [Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats.](#) Neuropharmacology. 2004; 47(8):1170-9.
71. Spano MS, Fattore L, Cossu G, Deiana S, **Fadda P**, Fratta W. [CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.](#) Br J Pharmacol. 2004 Oct;143(3):343-50.
72. Fattore L, Cossu G, Spano MS, Deiana S, **Fadda P**, Scherma M, Fratta W. [Cannabinoids and reward: interactions with the opioid system.](#) Crit Rev Neurobiol. 2004;16(1-2):147-58.
73. **Fadda P**, Scherma M, Fresu A, Collu M, Fratta W. [Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat.](#) Synapse. 2003 Oct;50(1):1-6.
74. Pinna GA, Cignarella G, Loriga G, Murineddu G, Mussinu JM, Ruiu S, **Fadda P**, Fratta W. [N-3\(9\)-arylpropenyl-N-9\(3\)-propionyl-3,9-diazabicyclo\[3.3.1\]nonanes as mu-opioid receptor agonists. Effects on mu-affinity of arylalkenyl chain modifications.](#) Bioorg Med Chem. 2002 Jun;10(6):1929-37.
75. Vianello P, Albinati A, Pinna GA, Lavecchia A, Marinelli L, Borea PA, Gessi S, **Fadda P**, Tronci S, Cignarella G. [Synthesis, molecular modeling, and opioid receptor affinity of 9, 10-diazatricyclo\[4.2.1.1\(2,5\)\]decanes and 2,7-diazatricyclo\[4.4.0.0\(3,8\)\]decanes structurally related to 3,8-diazabicyclo\[3.2.1\]octanes.](#) J Med Chem. 2000 Jun 1;43(11):2115-23.
76. **Fadda P**, Tronci S, Colombo G, Fratta W. [Differences in the opioid system in selected brain regions of alcohol-preferring and alcohol-nonpreferring rats.](#) Alcohol Clin Exp Res. 1999 Aug;23(8):1296-305.
77. Cignarella G, Barlocco D, Vianello P, Villa S, Pinna GA, **Fadda P**, Fratta W, Toma L, Gessi S. [Benzocondensed derivatives as rigid analogues of the mu-opioid agonist 3\(8\)-cinnamyl-8\(3\)-propionyl-3,8-diazabicyclo\[3.2.1\]octanes: synthesis, modeling, and affinity.](#) Farmaco. 1998 Oct-Nov;53(10-11):667-74.

78. Barlocco D, Cignarella G, Vianello P, Villa S, Pinna GA, **Fadda P**, Fratta W. [Synthesis and mu-opioid receptor affinity of a new series of nitro substituted 3,8-diazabicyclo\[3.2.1\]octane derivatives](#). *Farmaco*. 1998 Aug-Sep;53(8-9):557-62.
79. **Fadda P**, Barlocco D, Tronci S, Cignarella G, Fratta W. [Antinociceptive action of DBO 17 and DBO 11 in mice: two 3,8 diazabicyclo \(3.2.1.\) octane derivates with selective mu opioid receptor affinity](#). *Naunyn Schmiedebergs Arch Pharmacol*. 1997 Nov;356(5):596-602.
80. **Fadda P**, Fratta W. [Stress-induced sleep deprivation modifies corticotropin releasing factor \(CRF\) levels and CRF binding in rat brain and pituitary](#). *Pharmacol Res*. 1997 May; 35(5):443-6.
81. Castelli MP, Melis M, Mamei M, **Fadda P**, Diaz G, Gessa GL. [Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain](#). *Brain Res Mol Brain Res*. 1997 Apr;45(1):149-53.
82. Marrosu F, Pinna A, **Fadda P**, Fratta W, Morelli M. [C-Fos expression as a molecular marker in corticotropin-releasing factor-induced seizures](#). *Synapse*. 1996 Nov;24(3):297-304.
83. **Fadda P**, Pani L, Porcella A, Fratta W. [Chronic imipramine, L-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain](#). *Neurosci Lett*. 1995 Jun 9;192(2):121-3
84. Gessa GL, Pani L, **Fadda P**, Fratta W. [Sleep deprivation in the rat: an animal model of mania](#). *Eur Neuropsychopharmacol*. 1995;5 Suppl:89-93.
85. Pinna, G.A., Gavini, E., Cignarella, G., Scolastico, S., **Fadda, P**. [Synthesis and kappa binding affinity of 1-\(pyrrolidin-1-ylmethyl\)-2-\(N-methyl\)-4-\[\(3,4-dichloro\)phenyl\]-1,2,3,4 tetrahydroisoquinolin-3\(2H\)-ones](#). *Eur J Med Chem* 1995 30 (6), pp. 515-520
86. Barlocco D, Villa S, Fratta W, **Fadda P**, Colombo D, Toma L. [Monocyclic analogues of the mu-opioid agonist 3,8-diazabicyclo \[3.2.1\]octanes: Synthesis, modeling, and activity](#). *Tetrahedron* 51 (42), pp. 11547-11556
87. Barlocco D, **Fadda P**, Fratta W [Synthesis and opioid receptor affinity of bivalent ligands derived from 3,8-diazabicyclo\(3.2.1\)octanes](#). *Farmaco*. 1993 Mar;48(3):387-96.
88. **Fadda P**, Martellotta MC, Gessa GL, Fratta W. [Dopamine and opioids interactions in sleep deprivation](#). *Prog Neuropsychopharmacol Biol Psychiatry*. 1993 Mar;17(2):269-78.
89. **Fadda P**, Martellotta MC, De Montis MG, Gessa GL, Fratta W. [Dopamine D1 and opioid receptor binding changes in the limbic system of sleep deprived rats](#). *Neurochem Int*. 1992 Mar;20 Suppl:153S-156S.
90. **Fadda P**, Tortorella A, Fratta W. [Sleep deprivation decreases mu and delta opioid receptor binding in the rat limbic system](#). *Neurosci Lett*. 1991 Aug 19;129(2):315-7.
91. Demontis MG, **Fadda P**, Devoto P, Martellotta MC, Fratta W. [Sleep deprivation increases dopamine D1 receptor antagonist \[3H\]SCH 23390 binding and dopamine-stimulated adenylate cyclase in the rat limbic system](#). *Neurosci Lett*. 1990 Sep 4;117(1-2):224-7.

92. Mauri, A, Martellotta MC, **Fadda**, P, Mancuso S, Serri F, Argiolas, A. [Human placenta does not synthesize \$\alpha\$ -melanocyte stimulating hormone](#). Medical Science Research 1988 16 (16), pp. 877-878

Lista pubblicazione come Autore capitolo per testo universitario:

- FARMACOLOGIA F. Rossi, V. Cuomo, C. Riccardi - 2005
Edizioni Minerva Medica (cap. 16 Tossicodipendenza e sostanze D'abuso: Tabacco)
dal 01-01-2005 a oggi tre edizioni
- FARMACOLOGIA F. Rossi, V. Cuomo, C. Riccardi - 2005
Edizioni Minerva Medica (cap. 2 Farmacologia cellulare e molecolare: Peptidi oppioidi)
dal 01-01-2005 a oggi tre edizioni
- FARMACOLOGIA F. Rossi, V. Cuomo, C. Riccardi - 2005
Edizioni Minerva Medica (cap. 16 Tossicodipendenza e sostanze D'abuso: Allucinogeni)
dal 01-01-2005 a oggi tre edizioni
- FARMACOLOGIA F. Rossi, V. Cuomo, C. Riccardi - 2005
Edizioni Minerva Medica (cap. 16 Tossicodipendenza e sostanze D'abuso: Tabacco)
dal 01-01-2011 a oggi tre edizioni
- FARMACOLOGIA F. Rossi, V. Cuomo, C. Riccardi - II
edizione 2011 Edizioni Minerva Medica (cap. 16 Tossicodipendenza e sostanze D'abuso:
Allucinogeni) dal 01-01-2011 a oggi tre edizioni
- : FARMACOLOGIA F. Rossi, V. Cuomo, C. Riccardi - II
edizione 2011 Edizioni Minerva Medica (cap. 2 Farmacologia cellulare e molecolare: Peptidi
oppioidi) dal 01-01-2011 a oggi tre edizioni

COLLABORAZIONI SCIENTIFICHE CON GRUPPI DI RICERCA NAZIONALI ED INTERNAZIONALI

- **Eric R. Kandel**, Director KIBS , Fred Kavli Professor
Departments of Neuroscience, Psychiatry, Biochemistry & Molecular Biophysics, and
Physiology & Cellular Biophysics Columbia University, USA
Co-Director, Zuckerman Mind Brain Behavior Initiative
Senior Investigator, Howard Hughes Medical Institute
- **Denise Kandel**, Department of Epidemiology of Substance Abuse at the New York State
Psychiatric Institute, Professor of Sociomedical Sciences and Psychiatry, Columbia
University, USA.
- **Beat Lutz**, Institute of Physiological Chemistry, University Medical Center of the Johannes
Gutenberg University Mainz, Germany.
- **Steven R. Goldberg** Preclinical Pharmacology Section, Behavioral Neuroscience Research
Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes
of Health, Department of Health and Human Services, Baltimore, MD, USA.
- **Gernot Riedel**, School of Medical Sciences, College of Life Sciences and Medicine,
University of Aberdeen, Aberdeen, UK
- **Beat Lutz**, University of Mainz, Germany
- **Javier Fernández-Ruiz** Departamento de Bioquímica y Biología Molecular, Instituto
Universitario de Investigación en Neuroquímica, Universidad Complutense, Madrid, Spain
- **Roger Pertwee** Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
- **Alexander Makriyannis** Department of Pharmaceutical Sciences, Northeastern University,
Boston, Massachusetts, USA.

- **Robert Schwarcz** ,University of Maryland School of Medicine, Baltimore, Maryland 21228, USA.
- **Tiziana Rubino** Dept. of Theoretical and Applied Sciences, Biomedical Division and Center of Neuroscience; Univ. of Insubria, Busto Arsizio (VA), Italy
- **Daniela Parolaro** Fondazione Zardi Gori (Responsabile Scientifico)
- **Marco Andrea Riva** Department of Pharmacological and Biomolecular Sciences, Universita' degli Studi di Milano, Milan, Italy
- **Tiziana Bisogno** Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, 80078 Pozzuoli, Italy; Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy
- **Carlo Cifani** School of Pharmacy, Pharmacology Unit, University of Camerino, Italy
- **Claudio D'Addario** Faculty of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Italy